Minnesota Multiphasic Personality Inventory patterns before and after carbon dioxide inhalation therapy.
Explore the source record for details and available documents.
SEARCH · PubMed Health
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The Retec breathing assistor, with its gluidic valve, is an interesting method of providing assisted positive pressure inspiration, a resistive load to expiration and a capability for the administration of drugs by nebuliser. It requires some co-operation but very little training by patients, and is easily cleaned and maintained.
Many asthmatics complain of increased symptoms, awakenings, and need for additional medications during the sleeping hours. Sustained-release theophylline (THEO) may be superior to conventional inhaled bronchodilators in preventing nocturnal asthma symptoms and the early morning decrement in lung function common to this population. However, recent studies have demonstrated that THEO may delay sleep onset and perturb sleep stage distribution. No previous study has evaluated electroencephalographic, cardiac, and gas exchange indices during sleep in asthmatics treated with THEO compared with a long-acting inhaled beta 2-agonist. The study goals were to determine if theophylline perturbed sleep when compared with beta 2-agonists and to determine which agent achieved best control of daytime and nocturnal pulmonary symptoms and lung dysfunction. We evaluated 26 subjects with mild to moderate asthma and a history of frequent nocturnal symptoms who previously demonstrated decrements in AM lung function. THEO was compared with 3 puffs every 8 h (6 A.M., 2 P.M., and 10 P.M.) of bitolterol (BITOL), a long-acting beta 2-agonist, in a randomized, double-blind, placebo-controlled cross-over study. Each drug was administered for a 2-wk period ending with two consecutive nights of sleep evaluation followed by cross-over to the alternate drug regimen. During THEO administration, plasma concentrations on awakening were 11.4 +/- 0.69 micrograms/ml as compared with 0.00 micrograms/ml during BITOL. THEO was not found to disrupt sleep as sleep latency, total sleep time, percentage of total sleep time spent in Stages 1, 2, and 3/4 and in REM sleep were similar during each regimen.(ABSTRACT TRUNCATED AT 250 WORDS)
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
In Experiment I, four children with asthma were taught to use the intermittent positive-pressure breathing (IPPB) apparatus, a device that delivers bronchodilator medication to the lungs under positive pressure. Because these youngsters had not learned to use the device with repeated instructions, script with back-up reinforcement was introduced to train sequentially three responses - eye fixation, facial posturing, and diaphragmatic breathing - according to a multiple-baseline design. The procedures were effective in teaching appropriate use of the IPPB apparatus. Further, the children's use of the apparatus after training resulted in significantly more effective relief of asthma symptoms. In a second experiment, nurses were instructed in the application of the operant techniques used in the first study, and then served as experimenters in a partial replication of Experiment I. The data once again reflected a strong impact of the intervention program on IPPB responses.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.